May 2018, Vol 8, No 5

Verzenio Receives New Indication as Initial Treatment for Metastatic Breast Cancer

FDA Approvals, News & Updates, Breast Cancer, Breast Cancer

May 2018, Vol 8, No 5

What Will It Take for Oncology Practices to Survive?

By Gail Thompson

2018 Cancer Center Business Summit

May 2018, Vol 8, No 5

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

By Wayne Kuznar

Immunotherapy, NCCN Guideline Updates, National Comprehensive Cancer Network (NCCN)

May 2018, Vol 8, No 5

Cancer Vaccine plus Trastuzumab Shows Promise in HER2 Breast Cancer

By Rebecca Bailey

May 2018, Vol 8, No 5

Using Cancer Drugs Wisely to Control Costs: Targeted Therapies May Hold the Key

By Gail Thompson

2018 Cancer Center Business Summit

May 2018, Vol 8, No 5

Updated NCCN Prostate Cancer Guideline Emphasizes Risk Stratification

By Wayne Kuznar

NCCN Guideline Updates, National Comprehensive Cancer Network (NCCN)

May 2018, Vol 8, No 5

Managing Immune Checkpoint Inhibitor Side Effects: Key Recommendations

By Clark Westfield

Side-Effects Management

May 2018, Vol 8, No 5

Immunotherapies have transformed the treatment of cancer, but patients who receive immune checkpoint inhibitors may experience a range of side effects, which are only recently becoming familiar to oncologists and patients. Read More ›

Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC

By Charles Bankhead

May 2018, Vol 8, No 5

Immunotherapy plus Targeted Therapy Combination Active in Metastatic CRC

By Charles Bankhead

Immunotherapy, Immunotherapy

May 2018, Vol 8, No 5

Low Survival in Patients with Head and Neck Cancers Linked to Delays in Radiation Therapy After Surgery

By Corbin Davis

2018 Head and Neck Cancers Symposium, ASTRO Highlights

May 2018, Vol 8, No 5

Page 1 of 2

1
2

© Amplity Health. All Rights Reserved. Privacy Policy.